Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractBACKGROUND: Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus, has been used as vaccine delivery vector in preclinical and clinical studies against infectious diseases and malignancies. Here, we investigated whether an MVA which does not encode any antigen (Ag) could be exploited as adjuvant per se. METHODOLOGY/PRINCIPAL FINDINGS: We showed that dendritic cells infected in vitro with non-recombinant (nr) MVA expressed maturation and activation markers and were able to efficiently present exogenously pulsed Ag to T cells. In contrast to the dominant T helper (Th) 1 biased responses elicited against Ags produced by recombinant MVA vectors, the use of nrMVA as adjuvant for the co-administered soluble Ags resulted in a long lasting mixed Th1/Th2 responses. CONCLUSIONS/SIGNIFICANCE: These findings open new ways to potentiate and modulate the immune responses to vaccine Ags depending on whether they are co-administered with MVA or encoded by recombinant viruses.
CitationModified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. 2010, 5 (6):e11400 PLoS ONE
AffiliationDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
- Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
- Authors: Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB
- Issue date: 2009
- Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
- Authors: Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M
- Issue date: 2006 Mar
- Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
- Authors: Bohnen C, Wangorsch A, Schülke S, Nakajima-Adachi H, Hachimura S, Burggraf M, Süzer Y, Schwantes A, Sutter G, Waibler Z, Reese G, Toda M, Scheurer S, Vieths S
- Issue date: 2013 Aug
- Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.
- Authors: Liu L, Chavan R, Feinberg MB
- Issue date: 2008 Apr 15
- Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
- Authors: Ramírez JC, Gherardi MM, Esteban M
- Issue date: 2000 Jan